Clinicopathological and molecular pathological characteristics in tamoxifen‑related endometrial cancer

Tamoxifen (TAM), a selective estrogen receptor modulator, is often used for long-term adjuvant endocrine therapy in patients with hormone receptor-positive breast cancer. TAM is known to increase the risk of endometrial cancer (EC); however, the mechanism has not yet been fully elucidated. Therefore...

Full description

Saved in:
Bibliographic Details
Published inOncology letters Vol. 27; no. 1
Main Authors Saeki, Harumi, Horimoto, Yoshiya, Hlaing, May, Men, Yuan, Rong, Lu, Ishizuka, Yumiko, Uomori, Toshitaka, Yoshida, Emiko, Terao, Yasuhisa, Arakawa, Atsushi, Saito, Tsuyoshi, Yao, Takashi
Format Journal Article
LanguageEnglish
Published Athens Spandidos Publications UK Ltd 01.01.2024
D.A. Spandidos
Subjects
Breast cancer
Cloning
DNA methylation
Endocrine therapy
Endometrial cancer
Endometrium
Ethics
Growth factors
Investigations
Kinases
Ovaries
Protein expression
Proteins
Tumors
Japan
Online AccessGet full text

Cover

More Information
Summary:Tamoxifen (TAM), a selective estrogen receptor modulator, is often used for long-term adjuvant endocrine therapy in patients with hormone receptor-positive breast cancer. TAM is known to increase the risk of endometrial cancer (EC); however, the mechanism has not yet been fully elucidated. Therefore, molecular genetic analysis of EC following TAM administration (TAM-related EC) was conducted. A total of 10 samples of TAM-related EC and 20 sporadic EC samples (as controls) were analyzed. Copy number variation analysis was conducted, microsatellite instability (MSI) status was assessed, and mismatch repair (MMR) protein expression was examined immunohistochemically. Copy number variation analysis revealed that KDR, NOTCH1, NTRK1, NTRK3 and PDGFRB were more frequently amplified in TAM-related EC (P=0.039, P<0.001, P=0.011, P=0.006 and P=0.035, respectively). In MSI analysis, 4 cases were classified as MSI-high (40%), which is a higher frequency compared with that among patients with sporadic EC (~10% in Japanese women). Loss of MMR proteins was confirmed in all MSI-high cases. In 1 MSI-high case, a benign lesion of hyperplasia prior to EC development was also MSI-high with loss of some MMR protein expression. Several genes were specifically amplified in TAM-related ECs. Furthermore, TAM-related ECs were frequently MSI-high. Further studies are required to be conclusive; however, the present findings may lead to a reduction of unnecessary gynaecological testing in clinical practice and also encourage the testing for MSI status for optimal individualized treatment.
ISSN:1792-1074
1792-1082
DOI:10.3892/ol.2023.14142